- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00428571
Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients
Laparoscopic Bariatric Surgery for Treatment of Type 2 Diabetes in Obese Patients With End Organ Damage: A Prospective Randomized Controlled Pilot Study
A large number of research studies on people who were morbidly obese (extremely overweight), and had bariatric surgery (anti-obesity surgery) have shown that patients who were diabetic before surgery often experienced significant improvement in their diabetes following the surgery. For some patients, blood glucose levels returned to the normal range, and they were able to stop taking all of their diabetes medications. For others, blood glucose levels improved, allowing them to reduce their diabetes medications.
This research study is being done to determine whether bariatric surgery can safely provide better control of diabetes symptoms in obese diabetics than continuing medical management (anti-diabetic drugs in combination with diet and lifestyle changes).
There are several different types of bariatric surgery currently being used to treat morbid obesity. Two of the most common techniques are gastric bypass and adjustable gastric banding. This study will be comparing these two surgical techniques to treatment with a combination of drugs, diet, and lifestyle changes for control of type 2 diabetes.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 4A6
- St. Joseph's Healthcare
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Residents of Southern Ontario, Canada
Obese (BMI 30 to < 40 kg/m2) patients who have had type 2 diabetes mellitus for more than 5 years, complicated by at least one of the following situations that persist despite adequate management efforts. The complicating situations are:
- Severely reduced quality of life as assessed by the Audit of Diabetes Dependent Quality of Life (ADDQoL) questionnaire
- Metabolic lability/instability, characterized by two or more episodes of severe hypoglycemia (≤ 3mmol/L) or severe hyperglycemia (≥ 25 mmol/L), or two or more hospital visits for diabetic complications over the last year
Despite efforts at optimal glucose control, progressive secondary complications of diabetes as defined by:
- Retinopathy - a minimum of a three step progression using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading system, or an equivalent progression as certified by an ophthalmologist familiar with diabetic retinopathy or
- Nephropathy - persistent or progressive macroalbuminuria (>20 mg albumin/mmol creatinine) over at least 12 months (beginning anytime within the past two years) despite the use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) or
- Neuropathy - persistent or progressing autonomic neuropathy (gastroparesis, postural hypotension, neuropathic bowel or bladder) or persistent or progressing severe peripheral painful neuropathy not responding to usual management (e.g., tricyclics, gabapentin, or carbamazepine)
Exclusion Criteria:
- Less than 18 years of age or greater than 65 years of age
- Unable to complete self and interviewer administered questionnaires in English
- Incapable of providing informed consent
Any of the following medical conditions that may be associated with DM:
- Recent positive history of myocardial infarction or coronary artery bypass graft or percutaneous transluminal angioplasty (less than 6 months)
- Unstable angina pectoris
- Recent clinically important ST-T changes on electrocardiogram (ECG) over the past year
- Cardiac heart failure (New York Heart Association class III and IV; ejection fraction < 50%)
- Frequent and persistent and unstable supra and ventricular arrhythmias,
- Brain stroke, transient ischemic attack (TIA),
- Major diabetic foot infections
- Autonomic neuropathy resulting in orthostatic dysregulation
- History of any psychiatric illness that would make the patient a poor candidate for bariatric surgery, as determined by the study psychiatrist
- If female, pregnant or planning to become pregnant within next year
- Clinically important cancer history (impact on either lifespan or performance of lap. bariatric surgery)
- Clinically important abdominal or thoracic surgery that would impact the performance of laparoscopic bariatric procedure
- Insulin dependence for more than 10 years
- American Society of Anesthesiologists' classification of 4 or higher
- Severe gastrointestinal reflux disease with Grade 3 or 4 esophagitis
- History of pulmonary embolism or deep vein thrombosis
- Presently taking either high-dose steroids or anticoagulants
- Advanced nephropathy (Stage 4 or 5 - eGFR less than 30 ml/min)
- Any other condition that, in the opinion of the study surgeons, would make the patient a poor candidate for bariatric surgery
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador de Placebo: Intensive Medical Management
Medical management of obesity including medication optimization and lifestyle and dietary advice.
|
lifestyle, diet, medication optimization
|
|
Comparador Ativo: Laparoscopic Gastric Bypass
|
Laparoscopic Gastric Bypass Surgery
|
|
Comparador Ativo: Laparoscopic Adjustable Gastric Band
|
laparoscopic adjustable gastric banding
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Diabetic control as assessed by HbA1c
Prazo: 1 year
|
1 year
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Resolution of diabetes
Prazo: 1 year
|
1 year
|
|
Improvement in diabetic control and cardio-metabolic profile
Prazo: 1 year
|
1 year
|
|
Weight loss and decrease in BMI
Prazo: 1 year
|
1 year
|
|
Reduction in the usage of insulin or other diabetic drugs
Prazo: 1 year
|
1 year
|
|
Improvement in diabetic complications and end-organ damage
Prazo: 1 year
|
1 year
|
|
Improvement in health-related quality of life and depression scores
Prazo: 1 year
|
1 year
|
|
Utilization of resources and productivity losses
Prazo: 1 year
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 06-001
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .